CliffBio
biologic

Eloctate

Antihemophilic Factor (Recombinant), Fc Fusion protein

Loss of exclusivityJanuary 2029projected — 12-year biologic exclusivity estimate
CompanyBioverativ →See this company's full patent-cliff portfolio

Drug detail

Brand nameEloctate
Active ingredientAntihemophilic Factor (Recombinant), Fc Fusion protein
Strength4000IU
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalJanuary 2017
Marketing statusRx

More from Bioverativ

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Eloctate patent cliff — loss of exclusivity January 2029 | CliffBio